Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor

Georgina L. Thompson, J. Robert Lane, Thomas Coudrat, Patrick M. Sexton, Arthur Christopoulos, Meritxell Canals

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Biased agonism describes the ability of distinct G protein-coupled receptor (GPCR) ligands to stabilise distinct receptor conformations leading to the activation of different cell signalling pathways that can deliver different physiologic outcomes. This phenomenon is having a major impact on modern drug discovery as it offers the potential to design ligands that selectively activate or inhibit the signalling pathways linked to therapeutic effects with minimal activation or blockade of signalling pathways that are linked to the development of adverse on-target effects. However, the explosion in studies of biased agonism at multiple GPCR families in recombinant cell lines has revealed a high degree of variability on descriptions of biased ligands at the same GPCR and raised the question of whether biased agonism is a fixed attribute of a ligand in all cell types. The current study addresses this question at the mu-opioid receptor (MOP). Here, we have systematically assessed the impact of differential cellular protein complement (and cellular background), signalling kinetics and receptor species on our previous descriptions of biased agonism at MOP by several opioid peptides and synthetic opioids. Our results show that all these factors need to be carefully determined and reported when considering biased agonism. Nevertheless, our studies also show that, despite changes in overall signalling profiles, ligands that previously showed distinct bias profiles at MOP retained their uniqueness across different cell backgrounds.

Original languageEnglish
Pages (from-to)70-87
Number of pages18
JournalBiochemical Pharmacology
Volume113
DOIs
Publication statusPublished - 1 Aug 2016

Keywords

  • Biased agonism
  • Cell signalling
  • G protein-coupled receptors
  • Opioid receptor

Cite this

Thompson, Georgina L. ; Lane, J. Robert ; Coudrat, Thomas ; Sexton, Patrick M. ; Christopoulos, Arthur ; Canals, Meritxell. / Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. In: Biochemical Pharmacology. 2016 ; Vol. 113. pp. 70-87.
@article{dc59a76acfb2486c9f8d9e778a8f80c2,
title = "Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor",
abstract = "Biased agonism describes the ability of distinct G protein-coupled receptor (GPCR) ligands to stabilise distinct receptor conformations leading to the activation of different cell signalling pathways that can deliver different physiologic outcomes. This phenomenon is having a major impact on modern drug discovery as it offers the potential to design ligands that selectively activate or inhibit the signalling pathways linked to therapeutic effects with minimal activation or blockade of signalling pathways that are linked to the development of adverse on-target effects. However, the explosion in studies of biased agonism at multiple GPCR families in recombinant cell lines has revealed a high degree of variability on descriptions of biased ligands at the same GPCR and raised the question of whether biased agonism is a fixed attribute of a ligand in all cell types. The current study addresses this question at the mu-opioid receptor (MOP). Here, we have systematically assessed the impact of differential cellular protein complement (and cellular background), signalling kinetics and receptor species on our previous descriptions of biased agonism at MOP by several opioid peptides and synthetic opioids. Our results show that all these factors need to be carefully determined and reported when considering biased agonism. Nevertheless, our studies also show that, despite changes in overall signalling profiles, ligands that previously showed distinct bias profiles at MOP retained their uniqueness across different cell backgrounds.",
keywords = "Biased agonism, Cell signalling, G protein-coupled receptors, Opioid receptor",
author = "Thompson, {Georgina L.} and Lane, {J. Robert} and Thomas Coudrat and Sexton, {Patrick M.} and Arthur Christopoulos and Meritxell Canals",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.bcp.2016.05.014",
language = "English",
volume = "113",
pages = "70--87",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier",

}

Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. / Thompson, Georgina L.; Lane, J. Robert; Coudrat, Thomas; Sexton, Patrick M.; Christopoulos, Arthur; Canals, Meritxell.

In: Biochemical Pharmacology, Vol. 113, 01.08.2016, p. 70-87.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor

AU - Thompson, Georgina L.

AU - Lane, J. Robert

AU - Coudrat, Thomas

AU - Sexton, Patrick M.

AU - Christopoulos, Arthur

AU - Canals, Meritxell

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Biased agonism describes the ability of distinct G protein-coupled receptor (GPCR) ligands to stabilise distinct receptor conformations leading to the activation of different cell signalling pathways that can deliver different physiologic outcomes. This phenomenon is having a major impact on modern drug discovery as it offers the potential to design ligands that selectively activate or inhibit the signalling pathways linked to therapeutic effects with minimal activation or blockade of signalling pathways that are linked to the development of adverse on-target effects. However, the explosion in studies of biased agonism at multiple GPCR families in recombinant cell lines has revealed a high degree of variability on descriptions of biased ligands at the same GPCR and raised the question of whether biased agonism is a fixed attribute of a ligand in all cell types. The current study addresses this question at the mu-opioid receptor (MOP). Here, we have systematically assessed the impact of differential cellular protein complement (and cellular background), signalling kinetics and receptor species on our previous descriptions of biased agonism at MOP by several opioid peptides and synthetic opioids. Our results show that all these factors need to be carefully determined and reported when considering biased agonism. Nevertheless, our studies also show that, despite changes in overall signalling profiles, ligands that previously showed distinct bias profiles at MOP retained their uniqueness across different cell backgrounds.

AB - Biased agonism describes the ability of distinct G protein-coupled receptor (GPCR) ligands to stabilise distinct receptor conformations leading to the activation of different cell signalling pathways that can deliver different physiologic outcomes. This phenomenon is having a major impact on modern drug discovery as it offers the potential to design ligands that selectively activate or inhibit the signalling pathways linked to therapeutic effects with minimal activation or blockade of signalling pathways that are linked to the development of adverse on-target effects. However, the explosion in studies of biased agonism at multiple GPCR families in recombinant cell lines has revealed a high degree of variability on descriptions of biased ligands at the same GPCR and raised the question of whether biased agonism is a fixed attribute of a ligand in all cell types. The current study addresses this question at the mu-opioid receptor (MOP). Here, we have systematically assessed the impact of differential cellular protein complement (and cellular background), signalling kinetics and receptor species on our previous descriptions of biased agonism at MOP by several opioid peptides and synthetic opioids. Our results show that all these factors need to be carefully determined and reported when considering biased agonism. Nevertheless, our studies also show that, despite changes in overall signalling profiles, ligands that previously showed distinct bias profiles at MOP retained their uniqueness across different cell backgrounds.

KW - Biased agonism

KW - Cell signalling

KW - G protein-coupled receptors

KW - Opioid receptor

UR - http://www.scopus.com/inward/record.url?scp=84976640602&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2016.05.014

DO - 10.1016/j.bcp.2016.05.014

M3 - Article

VL - 113

SP - 70

EP - 87

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -